Washington Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $779K | Buy |
6,200
+1,800
| +41% | +$226K | 0.58% | 39 |
|
|
2025
Q1 | $487K | Sell |
4,400
-700
| -14% | -$77.4K | 0.39% | 77 |
|
|
2024
Q4 | $696K | Hold |
5,100
| – | – | 0.55% | 40 |
|
|
2024
Q3 | $588K | Buy |
5,100
+1,800
| +55% | +$207K | 0.45% | 65 |
|
|
2024
Q2 | $454K | Sell |
3,300
-700
| -18% | -$96.4K | 0.38% | 79 |
|
|
2024
Q1 | $552K | Sell |
4,000
-750
| -16% | -$103K | 0.45% | 76 |
|
|
2023
Q4 | $626K | Sell |
4,750
-1,000
| -17% | -$132K | 0.54% | 55 |
|
|
2023
Q3 | $647K | Hold |
5,750
| – | – | 0.59% | 46 |
|
|
2023
Q2 | $542K | Buy |
5,750
+750
| +15% | +$70.7K | 0.46% | 66 |
|
|
2023
Q1 | $506K | Hold |
5,000
| – | – | 0.45% | 73 |
|
|
2022
Q4 | $597K | Sell |
5,000
-1,500
| -23% | -$179K | 0.55% | 50 |
|
|
2022
Q3 | $690K | Hold |
6,500
| – | – | 0.7% | 39 |
|
|
2022
Q2 | $634K | Hold |
6,500
| – | – | 0.61% | 45 |
|
|
2022
Q1 | $609K | Hold |
6,500
| – | – | 0.5% | 56 |
|
|
2021
Q4 | $554K | Hold |
6,500
| – | – | 0.45% | 75 |
|
|
2021
Q3 | $623K | Hold |
6,500
| – | – | 0.55% | 46 |
|
|
2021
Q2 | $633K | Hold |
6,500
| – | – | 0.77% | 42 |
|
|
2021
Q1 | $632K | Hold |
6,500
| – | – | 0.59% | 51 |
|
|
2020
Q4 | $623K | Buy |
6,500
+1,100
| +20% | +$105K | 0.59% | 50 |
|
|
2020
Q3 | $519K | Buy |
+5,400
| New | +$519K | 0.53% | 67 |
|